Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.76 |
| ▸ | AKT2 | P31751 | 8/20 | 0.76 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25964331 | 0.93 | AKT1 (0.76) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL12420099 | 0.91 | AKT1 (0.79) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2192415 | 0.90 | AKT1 (0.80) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL30086167 | 0.86 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL2187875 | 0.86 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL29372652 | 0.86 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL26881159 | 0.86 | AKT1 (0.77) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL2172566 | 0.86 | AKT1 (0.85) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL2194123 | 0.86 | AKT1 (0.88) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL2177342 | 0.86 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | AKT1 3/4885AKT2 1/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.